Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab and Biomarker Assessment in nAMD
NCT07367282Phase 4Recruiting
- Start
- Jun 2026
- Primary completion
- Apr 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of faricimab in neovascular age-related macular degeneration (NVAMD). Started Jun 2026; status: recruiting.
02
Drugs
faricimab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07367282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07367282.